The proposed study intends to conduct a prospective analysis of data from approximately 700 patients who will receive this combination therapy as a 1L treatment for locally advanced or metastatic EGFR-mutated NSCLC in a real-world context. This evidence concerns the gene EGFR and non-small cell lung carcinoma.